Group 1 - Pfizer Inc. is set to release its fourth-quarter earnings results on February 3, with analysts expecting earnings of 57 cents per share, a decrease from 63 cents per share in the same period last year [1] - The consensus estimate for Pfizer's quarterly revenue is $16.83 billion, down from $17.76 billion a year earlier [1] Group 2 - Novavax, Inc. announced a license agreement with Pfizer for the use of its Matrix-M adjuvant on January 20 [2] - Following the announcement, Pfizer's shares increased by 1.4%, closing at $26.44 [2]

Financial Performance - H1 2025 sales reached €447 million, a 5.8% increase at current exchange rates and 6.1% at constant exchange rates[16] - Q2 2025 sales were €211 million, showing a 0.7% increase at current exchange rates and 3.3% at constant exchange rates[11] - Coach fragrance sales increased by 24% to €106.3 million in H1 2025[35] - Lacoste fragrance sales increased significantly by 42% to €52.2 million in H1 2025[61] - Montblanc fragrance sales decreased by 10% to €92.3 million in H1 2025[48] Regional Performance - North America experienced a 15% increase in sales during H1 2025[97] - Asia saw an 11% decrease in sales during H1 2025[108] - Western Europe experienced an 11% increase in sales during H1 2025[119] Strategic Initiatives - The company acquired intellectual property rights to Off-White® and Annick Goutal brands[19] - A fragrance license agreement was signed with Maison Longchamp through December 31, 2036, with the first women's line launching in 2027[19, 22] - The Coach license agreement was extended through 2031[19] Tariff Impact - The United States announced tariffs, initially at 20% and later reduced to 10%, with a proposed increase to 30% as of August 1, 2025[8] - Consumer prices are expected to increase by 6% to 7% as of August 1, 2025, with a limited impact on the group's profitability[10] Outlook - The company adjusted its 2025 sales guidance to around €910 million due to a slower start to H2 2025 and less favorable euro-dollar exchange rate[157, 159]